HPLC–MS–MS Indicates Resistant Hypertension in Non-Adherent Patients - - Chromatography Online
HPLC–MS–MS Indicates Resistant Hypertension in Non-Adherent Patients

E-Separation Solutions

A new study in the journal Heart suggests that high performance liquid chromatography tandem mass spectrometry (HPLC–MS–MS) could be performed as a standard screening tool to identify patients who do not take the anti-hypertensive medications as prescribed by their doctor. 1 The authors suggest that up to one in four patients is misdiagnosed as suffering with “resistant hypertension”, when in fact the patient has not been taking their prescribed medications as advised.1

It is estimated that around 10–20% of patients suffering with high blood pressure are resistant to standard anti-hypertensive drugs. Patients suffering with long-standing high blood pressure can be referred to specialist clinics for alternative therapies such as renal cauterization, where the nerve endings of the kidney artery walls are at a lower blood pressure.

It is however debated whether or not resistant hypertension is simply the result of not taking prescribed drugs as advised. The authors state that estimates of non-adherence range between 3­–65%. HPLC–MS–MS could be used as a useful screening tool prior to referral to specialist clinics.

The team spot sampled urine from 208 patients with long-standing high blood pressure who had been referred to a specialist hypertension clinic in Leeds, UK. HPLC–MS–MS was performed on the samples to detect the presence of a range of drugs known to be used in the treatment of hypertension.

Of the 208 patients tested, one in four patients were not taking their prescribed medication. Furthermore one in 10 samples did not contain any anti-hypertension medication. The average number of drugs in samples was also lower than expected.

The results suggest that HPLC–MS–MS could be used as a tool to screen for non-adherence to prescribed drug courses, however, the sample size is small and further investigations will need to be carried out in the future.

1. M. Tomaszewski, C. White, P. Patel, et al., Heart First Published Online: April 2, 2014) doi: 10.1136/heartjnl-2013-305


blog comments powered by Disqus
LCGC E-mail Newsletters
Global E-newsletters subscribe here:



Column Watch: Ron Majors, established authority on new column technologies, keeps readers up-to-date with new sample preparation trends in all branches of chromatography and reviews developments. LATEST: When Bad Things Happen to Good Food: Applications of HPLC to Detect Food Adulteration

Perspectives in Modern HPLC: Michael W. Dong is a senior scientist in Small Molecule Drug Discovery at Genentech in South San Francisco, California. He is responsible for new technologies, automation, and supporting late-stage research projects in small molecule analytical chemistry and QC of small molecule pharmaceutical sciences. LATEST: HPLC for Characterization and Quality Control of Therapeutic Monoclonal Antibodies

MS — The Practical Art: Kate Yu brings her expertise in the field of mass spectrometry and hyphenated techniques to the pages of LCGC. In this column she examines the mass spectrometric side of coupled liquid and gas-phase systems. Troubleshooting-style articles provide readers with invaluable advice for getting the most from their mass spectrometers. LATEST: Radical Mass Spectrometry as a New Frontier for Bioanalysis

LC Troubleshooting: LC Troubleshooting sets about making HPLC methods easier to master. By covering the basics of liquid chromatography separations and instrumentation, John Dolan is able to highlight common problems and provide remedies for them. LATEST: How Much Can I Inject? Part I: Injecting in Mobile Phase

More LCGC Columnists>>

LCGC North America Editorial Advisory Board>>

LCGC Europe Editorial Advisory Board>>

LCGC Editorial Team Contacts>>

Source: E-Separation Solutions,
Click here